VRNA - Multiplikator Forward P/S Verona Pharma
The launch of an innovative COPD treatment is driving revenue growth for Verona Pharma plc (VRNA), as evidenced by the price action on the GURU.Markets chart. The forward price-to-sales valuation demonstrates that the 41.30 mark is a relevant indicator. This trend reflects management's shift toward product commercialization and a flexible development model based on the full outsourcing of manufacturing and clinical trials.
Verona Pharma Inc. - rincian analitis lan metrik utama (VRNA)
- rega saham lan target rega konsensus:
- statistik kapitalisasi pasar:
- statistik nilai buku emiten:
- data utang lan likuiditas:
Utang marang Ekuitas Verona Pharma plc|VRNA - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal Verona Pharma plc|VRNA - Gunggung utang perusahaan|Utang marang nilai buku Verona Pharma Inc.|VRNA - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Verona Pharma|Rasio cepet veronapharma.com
- data bathi bisnis lan rasio investasi:
VRNA - Bathi pungkasan|Proyeksi bathi mangsa ngarep Verona Pharma plc|VRNA - Pangali P/E|Rega marang bathi mangsa ngarep Verona Pharma Corp|VRNA - Koefisien bali modal nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Verona Pharma Inc.|VRNA - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Verona Pharma|VRNA - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan veronapharma.com|VRNA - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Verona Pharma plc
- statistik dodolan lan pendapatan perusahaan:
Analisis fundamental perusahaan:Verona Pharma (VRNA)
The forward P/S ratio compares the current market value of Verona Pharma plc (VRNA) with expected revenue, determining the premium investors are willing to pay per unit of future sales. This metric's dynamics react sharply to operational data regarding drug commercialization, reflecting a revision of market expectations. Analyzing the forward P/S trend allows for an assessment of the value of innovations at Verona Pharma plc (VRNA), whose growth rates depend on the success of clinical trials rather than economic cycles.
Pesaing wigati
Haleon - Multiplikator forward rega marang pendapatan|Kenvue Inc - Rasio rega marang prakiraan pendapatan|Jyong Biotech Corp - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Ligand Corp|Amneal Pharmaceuticals (AMRX) - Rasio rega marang prakiraan pendapatan|perrigo.com - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Alvotech SA|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Liquidia Corp LQDA|Rasio rega marang prakiraan pendapatan Galapagos Genomics (GLPG)|ANI Pharmaceuticals Corp - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S MNKD (MannKind Corporation)|Multiplikator Forward P/S amphastar.com AMPH|PCRX: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan SPRY (ARS Pharmaceuticals Inc)|Theravance (TBPH) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan AQST (Aquestive Corp)|SCPH (scPharmaceuticals, Inc.) - Multiplikator Forward P/S|TECX: Rega forward marang dodolan|Multiplikator Forward P/S TNXP|Multiplikator Forward P/S sxtchina.com (SXTC)|Rasio rega marang prakiraan pendapatan Eupraxia Pharmaceuticals Inc. EPRX|Rega forward marang dodolan BHST|EXOZ - Rasio rega marang prakiraan pendapatan|Oramed Pharmaceuticals (ORMP) - Multiplikator forward rega marang pendapatan|ENTX: Multiplikator Forward P/S|MindWalk Holdings, Inc. (HYFT) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan ABVC|CPIX: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Quantum BioPharma Ltd (QNTM)|FGEN: Rega mangsa ngarep marang pendapatan|Rasio rega marang prakiraan pendapatan Telomir Pharmaceuticals, Inc. TELO|Rani Therapeutics Holdings - Rasio rega marang prakiraan pendapatan|Synergy CHC Corporation - Multiplikator Forward P/S|Rallybio Corporation (RLYB) - Multiplikator forward rega marang pendapatan|LEXX (lexariabioscience.com) - Multiplikator forward rega marang pendapatan|PULM (pulmatrix.com) - Rasio rega marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Pheton Holdings Limited|APM: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Lyra Therapeutics, Inc (LYRA)|Impact BioMedical, Inc. - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S TNFA (TNF Pharmaceuticals, Inc.)|Multiplikator Forward P/S cbdMD Inc. YCBD|PRFX - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan CYTO|LIPO: Multiplikator Forward P/S|OptiNose Corp - Rega forward marang dodolan|PIRS (Pieris Pharmaceuticals) - Multiplikator Forward P/S|Multiplikator Forward P/S procapsgroup.com|Rasio rega marang prakiraan pendapatan Petros Pharmaceuticals, Inc. (PTPI)|QLI (Qilian International Holding Group) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan ACELYRIN, Inc. SLRN|TFFP - Multiplikator forward rega marang pendapatan
